ICaPath
ICaPath is dedicated to pioneering breakthrough therapies for cancer treatment through its proprietary PLGA nanoparticle platform. The company develops innovative immunotherapy solutions, including systemic immunostimulation and controlled delivery of cytokines like IL-12, to address significant unmet medical needs in oncology. With a focus on personalized medicine, ICaPath combines advanced drug delivery technology with immuno-surveillance systems to improve patient outcomes and meet regulatory pathways, aiming to revolutionize cancer care.
Industries
Nr. of Employees
small (1-50)
ICaPath
John Hopkins Tech Ventures, Fast Forward, 1812 Ashland Ave, Suite 100, Baltimore, MD 21205
Products
PLGA nanoparticle delivery platform
A nanoparticle-based delivery platform using PLGA to encapsulate biologics and enabling controlled, prolonged release and improved pharmacokinetic stability for immunotherapeutics.
Recombinant interleukin-12 therapeutic candidate (PLGA-encapsulated)
A recombinant IL-12 protein candidate formulated for systemic, low-dose administration via PLGA encapsulation to provide sustained immune stimulation while addressing historical toxicity associated with high-dose unencapsulated IL-12.
Immuno-surveillance diagnostic assay (flow cytometry)
A diagnostic workflow for real-time analysis of immune status using fluorescent labeling and multi-parameter flow cytometry panels to quantify leukocyte subsets and activation/exhaustion markers for monitoring patients undergoing immunotherapy.
PLGA nanoparticle delivery platform
A nanoparticle-based delivery platform using PLGA to encapsulate biologics and enabling controlled, prolonged release and improved pharmacokinetic stability for immunotherapeutics.
Recombinant interleukin-12 therapeutic candidate (PLGA-encapsulated)
A recombinant IL-12 protein candidate formulated for systemic, low-dose administration via PLGA encapsulation to provide sustained immune stimulation while addressing historical toxicity associated with high-dose unencapsulated IL-12.
Immuno-surveillance diagnostic assay (flow cytometry)
A diagnostic workflow for real-time analysis of immune status using fluorescent labeling and multi-parameter flow cytometry panels to quantify leukocyte subsets and activation/exhaustion markers for monitoring patients undergoing immunotherapy.
Services
Coordination and use of contract manufacturing organizations to produce recombinant cytokine and PLGA nanoparticle material under GMP for clinical supply.
Regulatory planning and engagement support including preparation for and participation in pre-IND discussions with regulatory authorities.
Flow cytometry-based immune monitoring including fluorescent labeling, multi-parameter staining, and analysis of leukocyte subsets and activation/exhaustion markers.
Management and licensing of patent-protected delivery technology, and preparation of investor-facing materials to support commercial partnerships.
Coordination and use of contract manufacturing organizations to produce recombinant cytokine and PLGA nanoparticle material under GMP for clinical supply.
Regulatory planning and engagement support including preparation for and participation in pre-IND discussions with regulatory authorities.
Flow cytometry-based immune monitoring including fluorescent labeling, multi-parameter staining, and analysis of leukocyte subsets and activation/exhaustion markers.
Management and licensing of patent-protected delivery technology, and preparation of investor-facing materials to support commercial partnerships.
Expertise Areas
- Nanoparticle drug delivery
- Immunotherapy development
- Immune monitoring and immuno‑surveillance
- Preclinical development and IND-enabling studies
Key Technologies
- PLGA nanoparticle encapsulation
- Controlled-release formulation
- Recombinant cytokine therapeutics (interleukin-12)
- Multi-parameter flow cytometry
News & Updates
Pre-IND Meeting with FDA
Presented pre-clinical data to FDA, outlining regulatory pathway for ICaPath's immunotherapy approach.
ICaPath's Novel Immunotherapy Technology
Details on the company's patented nanoparticle technology and its potential to meet significant medical needs.
Research on IL-12 Encapsulation
Studies demonstrating the safety and efficacy of IL-12 delivery via PLGA nanoparticles.
Global Patent Award for PLGA Nanoparticle Technology
Awarded in August 2024, recognizing a breakthrough in biologics delivery.
Pre-IND Meeting with FDA
Presented pre-clinical data to FDA, outlining regulatory pathway for ICaPath's immunotherapy approach.
ICaPath's Novel Immunotherapy Technology
Details on the company's patented nanoparticle technology and its potential to meet significant medical needs.
Research on IL-12 Encapsulation
Studies demonstrating the safety and efficacy of IL-12 delivery via PLGA nanoparticles.
Global Patent Award for PLGA Nanoparticle Technology
Awarded in August 2024, recognizing a breakthrough in biologics delivery.